{"id":"W3165123004","doi":"10.1136/annrheumdis-2021-eular.1633","title":"POS1047 IMPACT OF UPADACITINIB ON REDUCING PAIN IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS: RESULTS FROM TWO PHASE 3 TRIALS IN PATIENTS WITH INADEQUATE RESPONSE TO NON-BIOLOGIC OR BIOLOGIC DMARDs","year":2021,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Spondyloarthritis Studies and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"ca_institutions":"Université Laval","funders":"Samsung; Celgene; Biogen; Gilead Sciences; Sanofi; Amgen; Pfizer; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Psoriatic arthritis; Adalimumab; Placebo; Internal medicine; Concomitant; Minimal clinically important difference; Certolizumab pegol; Golimumab; Psoriasis; Tofacitinib; BASDAI; Arthritis; Randomized controlled trial; Oncology; Rheumatoid arthritis; Dermatology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002009453,0.001423299,0.003051683,0.0003924662,0.000507417,0.001493976,0.0007235211,0.001825508,0.006596187],"category_scores_gemma":[0.001933772,0.0005734999,0.004436593,0.0005271037,0.000946732,0.001347226,0.0003920292,0.004729574,0.001262626],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008975373,"about_ca_system_score_gemma":0.001017194,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001244998,"about_ca_topic_score_gemma":0.004379412,"domain_scores_codex":[0.9992228,0.0003695035,0.00006703794,0.0001045374,0.0000676456,0.000168506],"domain_scores_gemma":[0.9988945,0.0004017998,0.0002256511,0.00007252316,0.0001040672,0.0003014347],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8679211,0.008012968,0.002720544,0.002347549,0.0054887,0.0001388661,0.000147295,0.001554983,0.006720414,0.0002896377,0.004984089,0.09967387],"study_design_scores_gemma":[0.8380696,0.1402386,0.01319575,0.0002326279,0.002900475,0.0002354439,0.000118872,0.0009246283,0.0009303069,0.0002856119,0.002802385,0.00006571956],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9658135,0.0215755,0.000500307,0.002332599,0.0007892627,0.001213942,0.002745533,0.0001844248,0.004844915],"genre_scores_gemma":[0.9835771,0.00712565,0.0009272524,0.002121254,0.0003606738,0.001040682,0.002846673,0.00003456093,0.001966151],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.006596187,"threshold_uncertainty_score":0.02206641,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04583795643492511,"score_gpt":0.3569194491877229,"score_spread":0.3110814927527978,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}